Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Lifted to Hold by Wall Street Zen

Wall Street Zen upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a strong sell rating to a hold rating in a report issued on Sunday,Wall Street Zen reports.

LXRX has been the topic of a number of other reports. Cantor Fitzgerald began coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, September 28th. They set an “overweight” rating and a $8.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 21st. Finally, Zacks Research lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 3rd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Lexicon Pharmaceuticals presently has an average rating of “Hold” and an average price target of $5.70.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ:LXRX opened at $1.78 on Friday. The company has a current ratio of 10.62, a quick ratio of 10.56 and a debt-to-equity ratio of 0.32. The stock’s fifty day simple moving average is $1.81 and its two-hundred day simple moving average is $1.89. Lexicon Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $2.68. The stock has a market cap of $792.03 million, a PE ratio of -12.71 and a beta of 1.10.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 161.80% and a negative return on equity of 35.76%. The firm had revenue of $11.25 million for the quarter, compared to the consensus estimate of $4.14 million. As a group, analysts forecast that Lexicon Pharmaceuticals will post -0.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Siren L.L.C. raised its stake in shares of Lexicon Pharmaceuticals by 13.8% in the first quarter. Siren L.L.C. now owns 44,303,518 shares of the biopharmaceutical company’s stock valued at $69,113,000 after buying an additional 5,384,615 shares during the period. Renaissance Technologies LLC lifted its position in shares of Lexicon Pharmaceuticals by 508.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,600,500 shares of the biopharmaceutical company’s stock valued at $2,497,000 after buying an additional 1,337,246 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth $1,365,000. ADAR1 Capital Management LLC bought a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth $1,170,000. Finally, Bank of America Corp DE increased its holdings in Lexicon Pharmaceuticals by 415.3% in the 1st quarter. Bank of America Corp DE now owns 526,103 shares of the biopharmaceutical company’s stock worth $821,000 after acquiring an additional 424,006 shares during the last quarter. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals News Summary

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Lexicon posted a Q3 loss of $0.03 per share, narrower than the $0.06 loss analysts expected and the $0.04 loss a year earlier. Revenue of $11.25 million also topped estimates of about $4.14 million. Zacks earnings report
• Positive Sentiment: The Phase 3 SONATA-HCM trial is substantially overenrolled, with top-line results expected in Q1 2027. This could provide a significant upcoming clinical catalyst. Lexicon clinical and financial update
• Positive Sentiment: Lexicon said positive STENO1 safety data strengthen the benefit-risk profile for a ZYNQUISTA NDA resubmission, potentially advancing another path to value creation. Lexicon clinical and financial update
• Neutral Sentiment: Phase 1 clinical development of LX9851 is ongoing at Novo Nordisk; the update indicates continued progress but offered no new results or specific timeline. Lexicon clinical and financial update
• Negative Sentiment: Despite beating estimates, Lexicon still reported a quarterly loss, reflecting continued profitability risk as investors await clinical and regulatory progress.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and chronic diseases. The company uses its drug discovery platform to identify small-molecule treatments designed to target specific biological pathways, with an emphasis on metabolic, cardiovascular and neurological conditions.

Lexicon’s commercial products include INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in certain adults with heart failure or type 2 diabetes and chronic kidney disease.